From neuroimaging to daily functioning: A multimethod analysis of reward anticipation in people with schizophrenia.
Erin K Moran, Adam J Culbreth, Sridhar Kandala...
https://pubmed.ncbi.nlm.nih.gov/31464449/Actively Recruiting
Led by Hsiao-Ying Wey · Updated on 2025-01-09
12
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating how caffeine intake influences the learning process through reward feedback compared to a placebo. This study focuses on healthy adults aged 18 to 45 and aims to better understand the role of caffeine in dopamine-related reinforcement learning. The research explores interactions between adenosine 2A receptors and dopamine D2 receptors in the brain, which are important for learning and behavior, using advanced brain imaging techniques. Participants will take part in a double-blind randomized crossover study where they receive either a 200mg caffeine tablet or a placebo lactose tablet. Before each study day, participants undergo a 6-day period without caffeine, alcohol, or drugs and maintain regular sleep schedules. On the seventh day, they undergo simultaneous PETfMRI brain scans after taking the assigned tablet 20 minutes prior to scanning. These scans will measure dopamine receptor availability and brain activity during reinforcement learning and motor inhibition tasks. During the study visits, participants complete a Probabilistic Selection Task reinforcement learning and a GoNoGo task motor inhibition while being scanned. Researchers monitor dopamine D2D3 receptor availability with PET using a radioactive dye and brain activity with fMRI. The study also assesses salience attribution after scanning. Safety is monitored, and participants adherence to the washout period is required. The main outcomes include dopamine receptor availability and effects of caffeine on learning tasks during the scan. The total participation includes the washout and scan days, with follow-up assessments after the scan.
CONDITIONS
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
H
Hsiao-Ying Wey, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hsiao-Ying Wey
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Caffeine (200 mg, oral, pre-scan) | Placebo (oral lactose tablet, pre-scan) |
|---|---|---|
| What it is | Oral caffeine (200 mg) given to healthy adults 20 minutes before brain PET/MRI scan for research on dopamine signaling and reinforcement learning. | Oral lactose tablet (placebo) given 20 minutes before brain PET/MRI scan as a comparison for caffeine’s effects. |
| Role in trial | Experimental exposure designed to measure how caffeine affects brain dopamine receptor availability and reinforcement learning in healthy adults. | Reference condition to control for expectancy and isolate the effects of caffeine in the same participants. |
| Primary use or research question | To study the effect of caffeine on dopamine D2/D3 receptor availability and performance in reward-based learning tasks, as measured by PET and fMRI. | Serves as the baseline/control for assessing changes in brain dopamine activity and learning outcomes resulting from caffeine exposure. |
| How it is given or performed | Participants receive 200 mg oral caffeine 20 minutes before PET/MRI data collection. Behavioral tasks are performed during imaging. | Participants receive a matched oral lactose placebo 20 minutes prior to PET/MRI scan with identical imaging and behavioral task procedures. |
| Evidence status | Prior neuroimaging studies in healthy adults show caffeine increases striatal dopamine D2/D3 receptor availability, supporting the rationale of PET/MRI measurement in this trial. | Placebo does not affect striatal dopamine receptor availability and serves as a neutral comparison for experimental analysis. |
| Important limitations | The study includes only healthy adults who are regular caffeine users; findings may not generalize to individuals with psychiatric, neurologic, or cardiovascular conditions. Small sample size limits power to detect rare or subtle effects. Effects may differ outside the acute single-dose research setting. | Placebo is an inactive comparator and does not replicate effects of other psychoactive compounds. Comparable research settings may yield different placebo responses based on participant expectations and behavioral context. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 days
Participants abstain from caffeinated dietary sources, alcohol, and drugs while maintaining regular bed and wake times.
Daily ambulatory period with no visits
Duration - 1 day
Participants receive either a caffeine or placebo tablet 20 minutes prior to a PET/fMRI scan to assess the effects on reinforcement learning and dopamine receptor availability.
1 visit (in-person PET/fMRI scan day)
Duration - 6 days
Participants abstain from caffeinated dietary sources, alcohol, and drugs while maintaining regular bed and wake times before crossing over to the other treatment condition.
Daily ambulatory period with no visits
Duration - 1 day
Participants receive the alternate treatment (caffeine or placebo) 20 minutes prior to a PET/fMRI scan to assess the effects on reinforcement learning and dopamine receptor availability.
1 visit (in-person PET/fMRI scan day)
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Erin K Moran, Adam J Culbreth, Sridhar Kandala...
https://pubmed.ncbi.nlm.nih.gov/31464449/Sergi Ferré, Jordi Bonaventura, Dardo Tomasi...
https://pubmed.ncbi.nlm.nih.gov/26051403/Nora D Volkow, Gene-Jack Wang, Frank Telang...
https://pubmed.ncbi.nlm.nih.gov/18716203/N D Volkow, G-J Wang, J Logan...
https://pubmed.ncbi.nlm.nih.gov/25871974/J B Bedingfield, D A King, F A Holloway
https://pubmed.ncbi.nlm.nih.gov/9768563/Valtteri Kaasinen, Sargo Aalto, Kjell Någren...
https://pubmed.ncbi.nlm.nih.gov/15076753/Hsiao-Ying Wey
Lead Sponsor